You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 9,795,620


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,795,620
Title:Oral composition of celecoxib for treatment of pain
Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37.degree. C..+-.0.5.degree. C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Inventor(s): Baheti; Ankit (Indore, IN), Padhi; Bijay Kumar (Buguda, IN), Vakada; Supritha (Hyderabad, IN), Raghuvanshi; Rajeev Singh (Gurgaon, IN)
Assignee: Dr. Reddy's Laboratories, Ltd. (Hyderabad, Telangana, IN)
Application Number:15/374,951
Patent Claims: 1. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 20% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

2. The method of claim 1, wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters: AUC.sub.(0-15 min) from about 10 ngh/mL to about 80 ngh/mL; AUC.sub.(0-30 min) from about 80 ngh/mL to about 400 ngh/mL; AUC.sub.(0-1 hr) from about 400 ngh/mL to about 1500 ngh/mL; AUC.sub.(0-2 hr) from about 1000 ngh/mL to about 4000 ngh/mL; AUC.sub.(0-t) at least about 2000 ngh/mL; AUC.sub.(0-.infin.) of at least about 2000 ngh/mL; and T.sub.lag of not more than 8 minutes.

3. The method of claim 1, wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

4. The method claim 1, wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

5. The method of claim 1, wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

6. The method of claim 5, wherein said composition has a pH of from about 3 to about 7.

7. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 40% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

8. The method of claim 7, wherein said reduced dose of celecoxib is about 240 mg.

9. The method of claim 7, wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters: AUC.sub.(0-15 min) from about 10 ngh/mL to about 80 ngh/mL; AUC.sub.(0-30 min) from about 80 ngh/mL to about 400 ngh/mL; AUC.sub.(0-1 hr) from about 400 ngh/mL to about 1500 ngh/mL; AUC.sub.(0-2 hr) from about 1000 ngh/mL to about 4000 ngh/mL; AUC.sub.(0-t) at least about 2000 ngh/mL; AUC.sub.(0-.infin.) of at least about 2000 ngh/mL; and T.sub.lag of not more than 8 minutes.

10. The method claim 7, wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

11. The method of claim 10, wherein said pain is associated with migraine.

12. The method claim 7, wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

13. The method of claim 7, wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

14. The method of claim 13, wherein said composition has a pH of from about 3 to about 7.

15. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 55% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

16. The method claim 15, wherein said reduced dose of celecoxib is about 180 mg.

17. The method of claim 15, wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters: AUC.sub.(0-15 min) from about 10 ngh/mL to about 80 ngh/mL; AUC.sub.(0-30 min) from about 80 ngh/mL to about 400 ngh/mL; AUC.sub.(0-1 hr) from about 400 ngh/mL to about 1500 ngh/mL; AUC.sub.(0-2 hr) from about 1000 ngh/mL to about 4000 ngh/mL; AUC.sub.(0-t) at least about 2000 ngh/mL; AUC.sub.(0-.infin.) of at least about 2000 ngh/mL; and T.sub.lag of not more than 8 minutes.

18. The method of claim 15, wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

19. The method of claim 18, wherein said pain is associated with migraine.

20. The method claim 15, wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

21. The method of treating pain of claim 15, wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

22. The method of treating pain of claim 21, wherein said composition has a pH of from about 3 to about 7.

23. A method of treating pain in a human subject, the method comprising administering to the subject a stable oral pharmaceutical composition, comprising a reduced dose of celecoxib and at least one pharmaceutically acceptable excipient, wherein said dose of celecoxib is at least about 70% less than conventional celecoxib in 400 mg oral capsules, and wherein said composition is devoid of cyclodextrin as a functional excipient.

24. The method of claim 23, wherein said reduced dose of celecoxib is about 120 mg.

25. The method claim 23, wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters: AUC.sub.(0-15 min) from about 10 ngh/mL to about 80 ngh/mL; AUC.sub.(0-30 min) from about 80 ngh/mL to about 400 ngh/mL; AUC.sub.(0-1 hr) from about 400 ngh/mL to about 1500 ngh/mL; AUC.sub.(0-2 hr) from about 1000 ngh/mL to about 4000 ngh/mL; AUC.sub.(0-t) at least about 2000 ngh/mL; AUC.sub.(0-.infin.) of at least about 2000 ngh/mL; and T.sub.lag of not more than 8 minutes.

26. The method of claim 23, wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain.

27. The method of claim 26, wherein said pain is associated with migraine.

28. The method of claim 23, wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition.

29. The method of treating pain of claim 23 wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture.

30. The method of treating pain of claim 29, wherein said composition has a pH of from about 3 to about 7.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.